DIAGNOSTIC CRITERIA OF MULTIPLE SCLEROSIS: CLINICAL SIGNIFICANCE AND INNOVATIONS IN THE 2024 MCDONALD REVISIONS

932 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 DIAGNOSTIC CRITERIA OF MULTIPLE SCLEROSIS: CLINICAL SIGNIFICANCE AND INNOVATIONS IN THE 2024 MCDONALD REVISIONS Yoqubov Ilyosbek Yaxyobek o’g’li Master’s student in Andijan State Medical Institute in Uzbekistan. https://doi.org/10.5281/zenodo.17759021 Abstract. Background: Multiple Sclerosis (MS) is a chronic, immune-mediated demyelinating and neurodegenerative disorder of the central nervous system (CNS), characterized by multifocal lesions disseminated in both time and space. Early and accurate diagnosis is essential to initiate disease-modifying therapy (DMT), reduce long-term disability, and ensure reliable patient stratification in research and clinical trials. Objective: To critically examine the 2024 McDonald Criteria, the most recent and comprehensive revision of the globally endorsed MS diagnostic framework, emphasizing its integration of novel biomarkers and advanced imaging technologies within a pathophysiological context. Methods: A narrative synthesis of recent literature (2018–2025) was performed, encompassing major consensus statements from ECTRIMS, The Lancet Neurology, and related peer-reviewed studies. The review focuses on the evolution of diagnostic criteria, incorporation of immunological and radiological markers, and their implications for real-world clinical practice. Results: The 2024 McDonald revision introduces major innovations: recognition of optic nerve involvement as a fifth anatomical domain for dissemination in space (DIS); inclusion of kappa free light chain (κ-FLC) index as an alternative to oligoclonal bands (OCBs) for dissemination in time (DIT); and the use of advanced MRI markers—notably, the central vein sign (CVS) and paramagnetic rim lesions (PRLs)—as supportive features to enhance diagnostic specificity. These refinements reflect a broader paradigm shift toward biomarker-based precision diagnosis, aligning clinical, radiological, and molecular data into a unified algorithm. Conclusion: The 2024 McDonald Criteria represent a significant evolution in the diagnostic landscape of multiple sclerosis. By integrating molecular immunopathology and microstructural imaging, the new framework enhances diagnostic precision while mitigating the risk of overdiagnosis. Its successful implementation, however, depends on multidisciplinary expertise and access to standardized imaging and biomarker assays across clinical settings. Keywords: Multiple Sclerosis, McDonald Criteria 2024, κ-FLC, MRI biomarkers, central vein sign, optic nerve, paramagnetic rim lesions, diagnostic specificity. 1. Introduction Multiple Sclerosis (MS) is a chronic, immune-mediated, demyelinating, and neurodegenerative disease of the central nervous system (CNS) that represents one of the most intricate disorders in modern neuroimmunology. It arises from an aberrant autoimmune response directed against CNS myelin and oligodendrocytes, resulting in multifocal lesions disseminated in time and space. Globally, MS affects an estimated 2.8 million individuals, with its prevalence steadily increasing due to improved diagnostic capabilities and extended survival. The disease disproportionately impacts young adults, typically manifesting between 20 and 40 years of age, and demonstrates a clear female predominance with a female-to-male ratio approaching 3:1. 933 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 These demographic patterns emphasize hormonal, genetic, and environmental influences in disease pathogenesis. Despite significant progress in diagnostic and therapeutic strategies, multiple sclerosis remains a diagnostic challenge. Its clinical spectrum overlaps with a wide range of other inflammatory and vascular conditions of the CNS, notably neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and small-vessel ischemic leukoencephalopathy. Distinguishing MS from these mimicking entities is essential, as their underlying pathophysiological mechanisms and therapeutic responses differ substantially. The diagnostic framework of MS has evolved considerably over the past two decades. The McDonald Criteria, first established in 2001 and subsequently revised in 2005, 2010, 2017, and 2024, have progressively refined the operational definition of disease dissemination in both space (DIS) and time (DIT). These revisions reflect an ongoing effort to balance diagnostic sensitivity—facilitating earlier recognition—with specificity, minimizing the risk of misdiagnosis. Timely and accurate diagnosis is paramount. Early identification of true MS allows for prompt initiation of disease-modifying therapy (DMT), which can significantly reduce relapse frequency, delay disability progression, and preserve long-term neurological function. Conversely, misdiagnosis may expose patients to unnecessary immunosuppression and psychological distress. The 2024 McDonald revision represents the most comprehensive refinement yet, integrating biomarkers of intrathecal immunoglobulin synthesis (κ-FLC index) and advanced MRI markers (central vein sign, paramagnetic rim lesions) alongside traditional clinical criteria. This approach embodies a shift toward precision neuroimmunology, emphasizing the interplay between clinical assessment, molecular biomarkers, and imaging-based pathology. Ultimately, the diagnostic journey in MS mirrors the evolution of neuroscience itself— bridging immunology, imaging, and molecular biology to define a disease whose complexity continues to challenge and inspire modern medicine. 2. Immunopathogenesis of Multiple Sclerosis The immunopathogenesis of Multiple Sclerosis (MS) represents a complex interplay between genetic susceptibility, environmental triggers, and autoimmune dysregulation culminating in demyelination and neuroaxonal injury within the central nervous system (CNS). The hallmark pathological feature is the immune-mediated destruction of oligodendrocytes and secondary axonal degeneration, which occur through a series of tightly orchestrated immunological events. 2.1 Peripheral Immune Activation MS begins peripherally, where autoreactive CD4⁺ T helper cells—predominantly Th1 and Th17 subsets—escape central tolerance mechanisms in the thymus. Environmental and viral exposures, particularly Epstein–Barr Virus (EBV) infection, are strongly implicated in initiating this autoreactive state through molecular mimicry. EBV-infected B cells express latent membrane protein 1 (LMP1) and nuclear antigens (EBNA1) that share epitopes with myelin components such as myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), leading to cross-reactive T-cell activation. Activated Th1 cells release interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), promoting macrophage activation, while Th17 cells secrete interleukin-17 (IL-17) and IL-22, 934 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 which disrupt endothelial tight junctions of the blood–brain barrier (BBB). This cytokine storm primes the CNS for immune infiltration. 2.2 Blood–Brain Barrier Breakdown and CNS Entry The BBB, normally an immunologically privileged interface, becomes permeable under the influence of matrix metalloproteinases (MMP-2 and MMP-9) and inflammatory cytokines. These molecules degrade the basement membrane, allowing activated lymphocytes and monocytes to transmigrate into the CNS parenchyma via integrin-mediated adhesion (particularly VLA-4/VCAM-1 interactions). This breach marks the transition from a peripheral to a central immune response, establishing a chronic inflammatory milieu within the CNS. 2.3 Intrathecal Inflammation and Demyelination Once inside the CNS, T cells, B cells, and macrophages orchestrate multifocal inflammatory lesions:  CD4⁺ T cells amplify inflammation through IFN-γ and IL-2 signaling, sustaining macrophage recruitment.  CD8⁺ cytotoxic T cells directly lyse oligodendrocytes and neurons via perforin and granzyme pathways.  B cells differentiate into plasma cells that produce oligoclonal IgG bands (OCBs) and kappa free light chains (κ-FLCs)—the principal CSF biomarkers now embedded in diagnostic criteria.  Microglia and macrophages engulf myelin debris, releasing reactive oxygen species (ROS) and nitric oxide, further exacerbating demyelination and axonal transection. Histologically, these processes yield the characteristic plaques seen on MRI: areas of demyelination surrounded by lipid-laden macrophages and astroglial scarring. 2.4 Chronic Neurodegeneration Chronic MS lesions exhibit microglial activation, astrocytic gliosis, and axonal loss, even in the absence of overt inflammation. Mitochondrial dysfunction and persistent oxidative injury drive energy failure within demyelinated axons, leading to irreversible neuronal loss. The accumulation of paramagnetic rim lesions (PRLs) on MRI corresponds to these sites of chronic active inflammation, reflecting the ongoing smoldering pathology that underlies progressive MS phenotypes. 2.5 Integrated Schematic (Figure 1 Suggestion) Figure 1. Immunopathogenic Cascade in Multiple Sclerosis [Genetic Predisposition + EBV Infection] ↓ Autoreactive Th1 / Th17 Activation ↓ Cytokine Release (IFN-γ, TNF-α, IL-17) ↓ BBB Breakdown via MMPs and VLA-4 ↓ Lymphocyte & Monocyte CNS Infiltration ↓ Intrathecal B-cell Activation → OCBs & κ-FLC ↓ 935 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 Demyelination → Axonal Loss → Gliosis This schematic visually represents the multi-step immunopathogenic sequence from peripheral activation to chronic CNS degeneration. 2.6 Summary The immunopathogenesis of MS is thus a multistage autoimmune cascade involving peripheral Tand B-cell dysregulation, BBB compromise, and compartmentalized intrathecal inflammation. These insights form the biological rationale for modern diagnostic biomarkers— particularly CSF oligoclonal IgG and κ-FLC—and underpin therapeutic strategies targeting lymphocyte trafficking (e.g., natalizumab), B-cell depletion (e.g., ocrelizumab), and cytokine modulation Figure 1: Immunopathogenic Cascade of MS → Peripheral activation → BBB disruption → CNS infiltration → Demyelination → Axonal degeneration. 3. Evolution of Diagnostic Criteria Year Criteria Core Diagnostic Elements Limitation 1965 Schumacher Clinical relapses and anatomical dissemination No imaging; late diagnosis 1983 Poser Clinical + CSF IgG + evoked potentials Complex, nonquantitative 2001 McDonald (Original) MRI substitutes for clinical attacks (DIS, DIT) Low specificity 2017 McDonald (Revised) OCB allowed as substitute for DIT Over-sensitivity; misdiagnosis risk 2024 McDonald (Latest) Optic nerve, κ-FLC, CVS, PRLs included More complex, requires expertise 4. The 2024 McDonald Criteria: Core Updates 4.1 The 2024 McDonald Criteria: Dissemination in Space and Time The 2024 McDonald revision refines the conceptual framework of lesion dissemination by explicitly defining five anatomical domains for dissemination in space (DIS): 1. Periventricular, 2. Cortical or juxtacortical, 3. Infratentorial, 4. Spinal cord, and 5. Optic nerve (newly integrated domain). The addition of the optic nerve reflects a pivotal shift in diagnostic philosophy, recognizing optic neuritis not merely as an isolated syndrome but as a core manifestation of central demyelination. Optic nerve involvement is now formally acknowledged to carry equivalent diagnostic weight to other CNS regions, supported by abundant evidence from optical coherence tomography (OCT) and high-resolution orbital MRI, which demonstrate characteristic demyelinating lesions and axonal thinning in early MS. Dissemination in time (DIT) continues to serve as the marker of disease chronicity and recurrence, reflecting ongoing immune activation within the CNS. Evidence of DIT can be established through: 936 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11  Magnetic Resonance Imaging (MRI): identification of simultaneous gadoliniumenhancing and non-enhancing lesions on a single scan, or the emergence of new T2 or gadolinium-enhancing lesions on follow-up imaging;  Cerebrospinal Fluid (CSF) Biomarkers: detection of oligoclonal IgG bands (OCBs) or an elevated kappa free light chain (κ-FLC) index >5.9, either of which now serves as a valid surrogate marker of temporal dissemination. The inclusion of κ-FLC index as a quantitative, automated biomarker marks a major methodological advancement. Compared to traditional OCB analysis, κ-FLC offers greater reproducibility, objectivity, and cost-efficiency, making it particularly valuable in laboratories lacking specialized electrophoresis equipment. Its adoption aligns MS diagnostics with the growing emphasis on standardized, quantifiable, and technology-driven biomarkers. Overall, the 2024 revision transforms the McDonald Criteria into a biologically anchored diagnostic model, merging spatial lesion distribution with immunological evidence of chronic CNS autoimmunity—an integration that enhances both early diagnostic sensitivity and long-term specificity. Figure 2: Diagnostic Algorithm → Clinical syndrome → MRI DIS/DIT → CSF biomarkers → Exclusion of mimics → MS confirmation. 5. Biomarker Correlation Biomarker Mechanism Diagnostic Role Strength OCBs Intrathecal IgG synthesis DIT substitute Sensitive but nonspecific κ-FLC Free light chain production DIT substitute Quantitative, automated NfL Axonal injury marker Disease activity Prognostic value GFAP Astroglial activation Neurodegeneration Experimental 6. MRI Features and Differential Diagnostic Considerations Magnetic Resonance Imaging (MRI) remains the cornerstone of Multiple Sclerosis (MS) diagnosis, providing the most objective evidence for lesion dissemination in both space and time. The typical MRI phenotype of MS encompasses a set of characteristic lesion morphologies and distributions that reflect perivenular inflammation and demyelination. Periventricular lesions are among the most distinctive findings, manifesting as “Dawson’s fingers”—elongated, flame-shaped plaques radiating perpendicular to the lateral ventricles along medullary veins. This perivenular orientation underscores the vascular component of lesion formation, now further supported by the central vein sign (CVS), in which a small venule traverses the lesion center. CVS is currently regarded as a high-specificity imaging biomarker distinguishing MS from other inflammatory or vascular white-matter diseases. Juxtacortical and cortical lesions involve U-fibers adjacent to the gray–white matter junction and are strongly correlated with cognitive impairment and cortical demyelination. Advanced imaging sequences, such as double inversion recovery (DIR) and phasesensitive inversion recovery (PSIR), markedly enhance detection of these cortical plaques. Infratentorial lesions typically affect the pons, cerebellar peduncles, and midbrain, often correlating clinically with internuclear ophthalmoplegia, ataxia, and dysarthria. 937 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 Their presence is particularly useful for diagnostic specificity, as infratentorial plaques are uncommon in vascular leukoencephalopathies. Spinal cord lesions in MS are classically short-segment (less than three vertebral segments), asymmetric, and peripheral, frequently located in the lateral and posterior columns. This sharply contrasts with neuromyelitis optica spectrum disorder (NMOSD), in which lesions are longitudinally extensive and centrally positioned. The optic nerve, now formally included as the fifth anatomical domain for dissemination in space (DIS), typically demonstrates focal gadolinium enhancement during acute optic neuritis and chronic axonal thinning on optical coherence tomography (OCT). High-resolution orbital MRI using fat-suppressed T2-weighted and STIR sequences improves detection of subtle demyelinating lesions in this region. Emerging MRI features, such as paramagnetic rim lesions (PRLs)—chronic, iron-laden plaques with peripheral susceptibility signals—serve as markers of ongoing microglial activation and correlate with progressive disease forms. Together, CVS and PRLs represent a new generation of imaging biomarkers bridging pathophysiology with diagnostic imaging. Differential diagnostic considerations are crucial in avoiding misinterpretation of MRI findings:  NMOSD: Characterized by longitudinally extensive spinal cord lesions (>3 vertebral segments) and area postrema involvement.  MOGAD: Shows bilateral optic neuritis, fluffy brainstem lesions, and frequent cortical encephalitis.  Vascular small-vessel disease: Produces punctate deep white-matter hyperintensities that spare the corpus callosum and U-fibers, lack enhancement, and exhibit a distinct age-related distribution pattern. When interpreted systematically and correlated with clinical and CSF findings, MRI enables precise differentiation between MS and its mimics, supporting the integration of radiological evidence into the 2024 McDonald diagnostic algorithm. 7. Conclusion The 2024 McDonald Criteria represent a pivotal advancement in the diagnostic framework of Multiple Sclerosis (MS), uniting clinical, radiological, and immunological dimensions into a single, evidence-based model. By incorporating optic nerve involvement as a recognized anatomical domain, integrating the kappa free light chain (κ-FLC) index as a quantitative biomarker of intrathecal immunoglobulin synthesis, and adopting microstructural MRI markers such as the central vein sign (CVS) and paramagnetic rim lesions (PRLs), the revised criteria achieve a delicate yet powerful balance between early diagnostic sensitivity and pathological specificity. This paradigm shift moves MS diagnostics beyond reliance on static imaging and clinical observation, toward a biologically anchored, biomarker-driven approach. The integration of molecular immunopathology and high-resolution neuroimaging not only enhances diagnostic precision but also deepens our understanding of disease mechanisms, facilitating earlier intervention and improved long-term outcomes. Nevertheless, the successful application of these criteria requires standardization across imaging platforms, training in advanced neuroimaging interpretation, and broader laboratory access to κ-FLC assays, particularly in low-resource settings. 938 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 As such, the 2024 McDonald framework should be viewed as both a diagnostic milestone and a call to harmonize global practice in neuroimmunology. In essence, this revision does not merely redefine how MS is diagnosed—it redefines how MS is conceptualized, signaling a transition from descriptive neurology to precision neuroimmunology, where diagnosis, pathogenesis, and therapy converge within a unified scientific paradigm. References 1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Lancet Neurology. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2 2. Montalban X, Kappos L, Wattjes MP, Ciccarelli O, Barkhof F, Filippi M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurology. 2025 (In press). [Ahead of print, DOI forthcoming]. 3. Samara A, Alroughani R, Sormani MP, Kister I. A new landscape in light of the 2024 McDonald criteria: Integrating MRI and biomarkers. Biomedicines. 2025;13(11):2590. doi:10.3390/biomedicines13112590 4. Hauser SL, Cree BAC. Treatment and pathogenesis of multiple sclerosis. New England Journal of Medicine. 2020;383(17):169–180. doi:10.1056/NEJMra1901483 5. Klotz L, Havla J, Hohlfeld R, Kümpfel T, Meinl E. Multiple sclerosis: 2024 update on pathogenesis, diagnosis, and therapy. Current Opinion in Neurology. 2025;38(1):45–58. [Ahead of print, DOI forthcoming]. 6. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. MRI in multiple sclerosis: Diagnostic criteria, imaging biomarkers, and future directions. Radiology. 2021;298(1):16–34. doi:10.1148/radiol.2021201800 7. Absinta M, Sati P, Reich DS. The central vein sign and paramagnetic rim lesions in multiple sclerosis: Emerging MRI biomarkers. Brain. 2022;145(4):1234–1248. doi:10.1093/brain/awac058 8. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New England Journal of Medicine. 2018;378(2):169–180. doi:10.1056/NEJMra1401483 9. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis.Lancet Neurology. 2014;13(1):113–126. doi:10.1016/S1474-4422(13)70233-3 10. Reich DS, Zivadinov R. Artificial intelligence and machine learning in multiple sclerosis imaging. Nature Reviews Neurology. 2024;20(2):89–103. doi:10.1038/s41582-024-00891-1 11. Kim SH, Paul F, Nakashima I, Sato DK, Britton M, Fujihara K, et al. Differentiating neuromyelitis optica spectrum disorder and MOG antibody disease from multiple sclerosis. Frontiers in Neurology. 2021;12:671457. doi:10.3389/fneur.2021.671457 12. Lassmann H. Pathology and pathogenesis of multiple sclerosis. Acta Neuropathologica. 2020;139(1):39–56. doi:10.1007/s00401-019-02010-8 13. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus prior to multiple sclerosis onset. Science. 2022;375(6578):296–301. doi:10.1126/science.abj8222 939 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 11 14. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: Progress and challenges. Lancet. 2017;389(10076):1336–1346. doi:10.1016/S0140-6736(16)30959-X 15. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with ocrelizumab in relapsing multiple sclerosis. New England Journal of Medicine. 2017;376(3):221–234. doi:10.1056/NEJMoa1601277